CBG Biotech, LTD. CO.

CBG Biotech, LTD. CO., a for-profit limited liability company based in Solon, Ohio, manufactures and supplies solvent recycling and recovery systems to federal healthcare, laboratory, and industrial facilities as a prime contractor under full-and-open and small-business set-aside procurement vehicles. The vendor operates exclusively as a prime (100% of awards) across a 278-award footprint spanning more than two decades, with no subcontract role.

CBG Biotech's product portfolio centers on solvent recovery and recycling equipment, preventative maintenance services, and extended maintenance agreements for laboratory and medical facilities. Representative work includes a $24,444.75 purchase order from the Department of Veterans Affairs Veterans Integrated Service Network 23 for a lab solvent recycler (awarded September 2026, completion December 2026), a $22,413 CBG Recycler Agreement with VISN 10 covering solvent recovery systems and preventative maintenance through November 2028, a $21,320 definitive contract from the U.S. Department of Agriculture Food Safety and Inspection Service for annual maintenance agreements on two solvent recyclers at the FSIS Eastern Lab in Athens, Georgia (completion September 2027), and a $40,660 purchase order from VISN 7 for two Path True 2.5G MSLV 100 solvent recovery and recycling systems delivered to the Ralph H. Johnson VA Medical Center in Charleston, South Carolina. Work spans laboratory, healthcare, and specialty-chemical applications, with equipment maintained at customer sites nationwide.

Customer concentration skews sharply toward the Veterans Health Administration and Defense Health Agency. The top five customers account for 20% of award count but represent the VA's VISN network as the dominant buyer — VISN 7, VISN 10, and VISN 23 lead volume (15, 13, and 13 awards respectively), generating $786 thousand combined potential value. However, 74% of the combined potential value traces to GSA Federal Acquisition Service (2 awards, $3.9 million), indicating that CBG Biotech holds placement on GSA supply schedules that dwarf individual agency purchase orders. The vendor sits on Federal Supply Schedule GS07F9279S (48 task orders, $601 thousand combined potential value) and participates in the Scientific Equipment and Services vehicle (37 task orders, $609 thousand combined potential value), plus several additional GSA and specialty schedules. The 40 distinct agencies served span the VA system, Defense Health Agency, Department of Agriculture, Treasury Bureau of Engraving and Printing, and Department of the Navy.

Award activity has contracted significantly in recent years — eight awards in 2022 declined to four in 2024, one in 2025, and one in 2026 — suggesting a matured installed base with lower procurement velocity. The recent award pattern (as of late September 2026) reflects individual replacement and maintenance orders rather than new platform wins. Only four awards carry ultimate completion dates within the next twenty-four months, with combined potential value of $72 thousand, limiting near-term recompete exposure. NAICS concentration clusters around Analytical Laboratory Instrument Manufacturing (55 awards), reflecting CBG Biotech's core equipment-supply posture, with PSC coding anchored to Laboratory Equipment and Supplies (110 awards) and Medical and Surgical Instruments, Equipment, and Supplies (40 awards). Small-business set-aside designation appears on approximately one-third of awards; the remainder are full-and-open procurements, indicating the vendor competes and wins across both procurement channels without set-aside dependency.